Fig. 2.

Distribution of therapy groups by anti-TNF therapy at a the time of anti-TNF initiation and b during anti-TNF follow-up in the biologic-naive group, and at c the time of anti-TNF initiation and d during anti-TNF follow-up in the biologic-experienced group. ADL adalimumab, anti-TNF anti-tumor necrosis factor, CZP certolizumab pegol, ETN etanercept, GOL golimumab, IFX infliximab